港股通创新药ETF嘉实（520970）涨超5%！2025年我国批准上市的创新药达76个，创历史新高！

Group 1 - The core viewpoint of the news is that the A-share and Hong Kong markets are experiencing a collective rise, with the Shanghai Composite Index surpassing 4000 points, indicating positive market sentiment [1] - The Hong Kong Stock Connect innovative drug index increased by 3.85%, with notable individual stock performances such as Zhaoyan New Drug rising over 11% and Tigermed and Kelun-Bio rising over 6% [1] - According to a report by Changjiang Securities, Zhaoyan New Drug is expected to see a 60% year-on-year growth in offshore outsourcing orders in 2024, driven by domestic safety evaluation demand recovery and resource scarcity [1] Group 2 - The China National Medical Products Administration reported that 76 innovative drugs have been approved for market in China by 2025, setting a historical record [1] - The total amount of authorized transactions for innovative drugs in China has exceeded $130 billion, with over 150 transactions, also a historical high [1] - Currently, China's pipeline of new drugs accounts for approximately 30% of the global total, ranking second worldwide [1] Group 3 - The Hong Kong Stock Connect innovative drug ETF managed by Harvest (520970) has a management and custody fee of 0.60% per year, making it suitable for both retail investors as a long-term investment tool and for professional investors seeking flexible trading options [2]